Purinergic Signaling Dysfunction Validation in Parkinson's Disease

Migration, Crosslink

📖

Purinergic Signaling Dysfunction Validation in Parkinson's Disease

active

wiki page Created: 2026-04-02T07:20:09 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-experiments-purinergic-signaling-pa

📖 Wiki Page

experiment985 wordssynced 2026-04-02

Purinergic Signaling Dysfunction Validation in Parkinson's Disease

Experiment Overview

flowchart TD PURINERGIC["Purinergic Signaling"] PD["Parkinson's Disease"] PURINERGIC -->|"dysregulated in"| PD style PURINERGIC fill:#4fc3f7,stroke:#333,color:#000 style PD fill:#ef5350,stroke:#333,color:#000

Experiment ID: PUR-PD-001 Hypothesis: Purinergic signaling dysfunction (ATP/adenosine receptor signaling) is a primary upstream driver of alpha-synuclein aggregation, neuroinflammation, and dopaminergic neurodegeneration in PD. Phase: Preclinical + Clinical (Multi-phase) Duration: 36 months

Study Design

Phase 1: In Vitro Validation (Months 1-12)

1.1 P2X7R-Alpha-Synuclein Interaction

Objective: Determine whether P2X7R activation directly promotes alpha-synuclein aggregation and propagation.

Methods:

Primary rat midbrain neurons and iPSC-derived dopaminergic neurons from PD patients (LRRK2 G2019S, idiopathic)
Treatment groups:
Control (vehicle)
ATP (100 μM, 1h daily for 7 days) — P2X7R agonist
ATP + A-438079 (10 μM) — P2X7R antagonist rescue
Alpha-synuclein pre-formed fibrils (PFF, 2 μg/mL) — seed control
ATP + PFF — combined challenge

Endpoints:

Alpha-synuclein phosphorylation at Ser129 (pS129) — Western blot, ELISA
Oligomer formation — Thioflavin T fluorometry, SEC-MALS
Neuronal viability — MTT assay, MAP2 immunostaining
Calcium imaging — Fluo-4 AM live cell imaging
IL-1β/IL-18 release — Luminex cytokine panel

...

Purinergic Signaling Dysfunction Validation in Parkinson's Disease

Experiment Overview

Mermaid diagram (expand to render)

Experiment ID: PUR-PD-001 Hypothesis: Purinergic signaling dysfunction (ATP/adenosine receptor signaling) is a primary upstream driver of alpha-synuclein aggregation, neuroinflammation, and dopaminergic neurodegeneration in PD. Phase: Preclinical + Clinical (Multi-phase) Duration: 36 months

Study Design

Phase 1: In Vitro Validation (Months 1-12)

1.1 P2X7R-Alpha-Synuclein Interaction

Objective: Determine whether P2X7R activation directly promotes alpha-synuclein aggregation and propagation.

Methods:

Primary rat midbrain neurons and iPSC-derived dopaminergic neurons from PD patients (LRRK2 G2019S, idiopathic)
Treatment groups:
Control (vehicle)
ATP (100 μM, 1h daily for 7 days) — P2X7R agonist
ATP + A-438079 (10 μM) — P2X7R antagonist rescue
Alpha-synuclein pre-formed fibrils (PFF, 2 μg/mL) — seed control
ATP + PFF — combined challenge

Endpoints:

Alpha-synuclein phosphorylation at Ser129 (pS129) — Western blot, ELISA
Oligomer formation — Thioflavin T fluorometry, SEC-MALS
Neuronal viability — MTT assay, MAP2 immunostaining
Calcium imaging — Fluo-4 AM live cell imaging
IL-1β/IL-18 release — Luminex cytokine panel

Power Analysis: n=6 per group; 80% power to detect 30% difference in pS129, α=0.05

1.2 A2AR-Mediated Aggregation Kinetics

Objective: Characterize how A2AR signaling modulates alpha-synuclein aggregation kinetics.

Methods:

Recombinant alpha-synuclein aggregation assay (ThT kinetic assay)
Treatment with:
CGS-21680 (100 nM) — A2AR agonist
SCH-58261 (100 nM) — A2AR antagonist
Forskolin (10 μM) — direct cAMP activator
H-89 (10 μM) — PKA inhibitor

Endpoints:

Aggregation half-time (T50)
Maximum ThT fluorescence (Fmax)
Morphology of aggregates — TEM
Phosphorylation at Ser129, Tyr125 — mass spectrometry

1.3 Astrocytic P2Y1R Metabolic Coupling

Objective: Determine how P2Y1R signaling modulates astrocyte-neuron metabolic coupling.

Methods:

Co-culture of primary astrocytes and neurons
[U-13C]glucose metabolic tracing
P2Y1R agonist (MRS2365, 100 nM) and antagonist (MRS2500, 1 μM)

Endpoints:

Lactate release (13C labeling)
Glutamate uptake (functional assay)
GLT-1 expression — Western blot
Neuronal ATP levels — Luciferin-luciferase assay

Phase 2: Animal Model Validation (Months 12-24)

2.1 P2X7R Antagonism in MPTP Model

Objective: Test whether P2X7R antagonism provides neuroprotection in MPTP-induced parkinsonism.

Animals: C57BL/6 mice, 10-12 weeks, male (n=48)

Groups:

Saline control

MPTP (30 mg/kg, i.p., 5 days)

MPTP + Brilliant Blue G (50 mg/kg, i.p., daily)

MPTP + A-438079 (30 mg/kg, i.p., daily)

MPTP + combination (P2X7R + A2AR antagonist)

A2AR antagonist (SCH-58261, 1 mg/kg) alone

Endpoints (at 7, 14, 30 days post-MPTP):

Behavioral: cylinder test, stepping test, grid test
Neurochemical: striatal dopamine (HPLC), tyrosine hydroxylase (IHC)
Neuroinflammation: Iba1+ microglial density, IL-1β levels (ELISA)
Alpha-synuclein: pS129 burden (IHC), oligomers (ELISA)
In vivo imaging: [11C]PK-11195 PET for microglial activation

2.2 A2AR Genetic Knockout Cross

Objective: Determine if A2AR deletion modifies alpha-synuclein pathology.

Animals: Thy1-αSyn (wild-type and A2AR-/-) (n=30)

Endpoints:

Motor behavior at 3, 6, 9 months
Dopaminergic neuron count (TH+ cells in SNc)
Alpha-synuclein burden and phosphorylation
Microglial activation state

Phase 3: Clinical Biomarker Validation (Months 18-36)

3.1 CSF Purinergic Biomarker Study

Objective: Validate extracellular ATP/ADP/adenosine levels as early PD biomarkers.

Cohort:

PD patients (n=80, Hoehn & Yahr 1-2)
Prodromal PD (RBD + hyposmia) (n=30)
Healthy controls (n=40)

Endpoints:

CSF ATP, ADP, adenosine (LC-MS/MS)
CSF IL-1β, IL-18 (Luminex)
CSF alpha-synuclein pS129 (Simoa)
Clinical: MDS-UPDRS, MoCA, olfactory function

Correlation Analysis: Biomarker levels vs. disease duration, motor severity, non-motor symptoms

3.2 PET Imaging of Purinergic Receptors

Objective: Image P2X7R and A2AR density in living PD brains.

Cohort: PD (n=20), HC (n=10)

Radiotracers:

[11C]A-740001 for P2X7R (or [18F]JNJ-64413739 if available)
[11C]SCH-442416 for A2AR

Analysis: PET-MRI quantification of receptor binding (SUVR) in striatum, substantia nigra, cortex

Primary Endpoints

| Endpoint | Method | Timepoint | Target Effect |
|----------|--------|-----------|---------------|
| pS129 alpha-synuclein | ELISA | Phase 1 | 40% reduction with antagonist |
| Dopaminergic neurons | TH+ IHC | Phase 2 | 30% protection |
| CSF ATP/ADP ratio | LC-MS/MS | Phase 3 | AUC >0.80 for PD vs. HC |
| Motor behavior | Cylinder test | Phase 2 | 25% improvement |

Statistical Analysis

Primary: Two-way ANOVA with Tukey's post-hoc (in vitro), mixed-effects model (in vivo)
Clinical: ROC curve analysis for biomarker discrimination, Pearson correlation for associations
Significance threshold: p < 0.05, FDR correction for multiple comparisons

Risk Mitigation

| Risk | Mitigation |
|------|------------|
| P2X7R antagonist blood-brain barrier penetration | Use BBB-permeable compounds (BBG, A-438079) |
| Inter-species differences | Validate key findings in human iPSC neurons |
| Biomarker variability | Standardize CSF collection protocol, same-center analysis |
| PET tracer availability | Identify alternative tracers, establish synthesis protocols |

Budget Estimate

| Category | Cost (USD) |
|----------|-----------|
| Phase 1 (in vitro) | $350,000 |
| Phase 2 (animal) | $500,000 |
| Phase 3 (clinical) | $650,000 |
| PET synthesis/imaging | $200,000 |
| Personnel (3 years) | $600,000 |
| Total | $2,300,000 |

Timeline

Month 1-6: Phase 1.1 (P2X7R-αSyn in vitro)
Month 6-12: Phase 1.2-1.3 (A2AR, astrocyte studies)
Month 12-18: Phase 2.1 (MPTP + P2X7R antagonist)
Month 18-24: Phase 2.2 (A2AR KO cross), Phase 3.1 initiation
Month 24-30: Phase 3.1 (CSF biomarker cohort)
Month 30-36: Phase 3.2 (PET imaging), data analysis

Ethical Considerations

Animal use: IACUC approval, 3Rs compliance (replacement, reduction, refinement)
Human subjects: IRB approval, informed consent, data protection (HIPAA/GDPR)
Sample handling: Standardized protocols, biobank integration

Success Criteria

In vitro: P2X7R antagonism reduces pS129 by ≥40% in human neurons

In vivo: P2X7R antagonist improves dopaminergic survival by ≥30%

Clinical: CSF ATP/ADP ratio discriminates PD from controls (AUC ≥0.80)

Translation: Identifies clinical-ready compound for rapid Phase II trial

Cross-Links to Hypothesis Page

[Purinergic Signaling Dysfunction Hypothesis](/hypotheses/purinergic-signaling-parkinsons)
[Purinergic Receptor Clinical Trials](/clinical-trials/purinergic-receptor-trials-parkinsons)
[Neuroinflammation Mechanism](/mechanisms/neuroinflammation-parkinsons)
[NLRP3 Inflammasome Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons)
[Alpha-synuclein Pathway](/mechanisms/synuclein-pathway-parkinsons)

References

[Schwartz R, et al. Purinergic signaling in neurodegenerative diseases (2018)](https://doi.org/10.1038/s41582-018-0031-8)

[Jenkinson R, et al. Adenosine A2A receptor antagonists in Parkinson's disease (2023)](https://doi.org/10.1212/WNL.0000000000207500)

📖 View canonical wiki page →

Related Entities

experiments-purinergic-signaling-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	experiments-purinergic-signaling-parkinsons
kg_node_id	None
entity_type	experiment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ef2eb9ccc7d9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'experiments-purinergic-signaling-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

85

Outgoing

86

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Purinergic Signaling Dysfunction Validation in Parkinson's Disease

Purinergic Signaling Dysfunction Validation in Parkinson's Disease

Experiment Overview

Study Design

Phase 1: In Vitro Validation (Months 1-12)

1.1 P2X7R-Alpha-Synuclein Interaction

Purinergic Signaling Dysfunction Validation in Parkinson's Disease

Experiment Overview

Study Design

Phase 1: In Vitro Validation (Months 1-12)

1.1 P2X7R-Alpha-Synuclein Interaction

1.2 A2AR-Mediated Aggregation Kinetics

1.3 Astrocytic P2Y1R Metabolic Coupling

Phase 2: Animal Model Validation (Months 12-24)

2.1 P2X7R Antagonism in MPTP Model

2.2 A2AR Genetic Knockout Cross

Phase 3: Clinical Biomarker Validation (Months 18-36)

3.1 CSF Purinergic Biomarker Study

3.2 PET Imaging of Purinergic Receptors

Primary Endpoints

Statistical Analysis

Risk Mitigation

Budget Estimate

Timeline

Ethical Considerations

Success Criteria

Cross-Links to Hypothesis Page

References

💬 Discussion